logo

PACB

Pacific Biosciences·NASDAQ
--
--(--)
--
--(--)
3.93 / 10
Netural

The fund flow profile scores 7.86/10, demonstrating robust fund flow characteristics. Favorable no significant trends movements are tempered by challenging overall, block, Small, Medium, Large, and Extra-large dynamics, supporting positive flow assessment. Research analyst consensus shows divided analyst consensus, demonstrating neutral perspective. Current ratings: Neutral(100.0%) across 1 coverage providers, supported by 0.00 historical weighted rating.

FundamentalSentiment(3.93)Technical
Fund Flow Rating
Analyst RatingStrong Buy

Wall Street Opinions

Strong Buy

Strong Buy

0%

Buy

0%

Hold

0%

Sell

0%

Strong Sell

0%

Date2025-12-15
InstitutionBarclays
Times predicted2
Historical Win Rate0.0%
What is the analyst consensus for PACB?
  • PACB holds a Bearish analyst rating, with 0% of experts assigning a Hold grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 3.93/10 (Netural).